Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea.
A multicentre double-blind, placebo-controlled clinical trial, involving 123 patients at 10 centres, was carried out to assess the efficacy of a preparation of lactic acid-producing Enterococcus SF 68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. In the prevention study, 45 patients being treated with antibiotics were given, concurrently, one capsule twice daily of either Enterococcus SF68 or placebo. Acute diarrhoea was present in 78 patients who were given the same treatment but three times daily. All treatments were continued for 7 days. Enterococcus SF 68 was shown to be effective in reducing the incidence of antibiotic-associated diarrhoea in comparison with placebo (8.7% compared with 27.2%, respectively). Patients with acute enteritis showed a significantly faster resolution of bowel abnormalities during treatment with Enterococcus SF68 compared with placebo.
Wunderlich
P F
PF
Department of Internal Medicine, District Hospital, Faido, Switzerland.
Braun
L
L
Fumagalli
I
I
D'Apuzzo
V
V
Heim
F
F
Karly
M
M
Lodi
R
R
Politta
G
G
Vonbank
F
F
Zeltner
L
L
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013291:Streptococcus / Q000276:immunology*; D014552:Urinary Tract Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines; C061439:Bioflorin